Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03996408
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03991975
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijin, Beijing, China
Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TQ-F3083 capsule 10 mgDrug: TQ-F3083 capsule 20 mgDrug: Linagliptin tabletDrug: TQ-F3083 blank analog capsuleDrug: Linagliptin blank analog tablet
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03986073
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03983928
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT03974594
- Locations
- 🇨🇳
Tangdu Hospital,Fourth Military Medical University, Xi'an, Shanxi, China
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT03972189
- Locations
- 🇨🇳
Tumor hospital, Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳Henan Tumor Hospital, Zhengzhou, Henan, China
🇨🇳Affiliated tumor hospital of sun yat-sen university, Guangzhou, Guangdong, China
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03910127
- Locations
- 🇨🇳
Gansu Province Tumor Hospital, Lanzhou, Gansu, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Henan Province Tumor Hospital, Luoyan, Henan, China
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03897283
- Locations
- 🇨🇳
Jilin Cancer Hospital, Chang chun, Jilin, China
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- Drug: TQB2450 Injection and Anlotinib Hydrochioride Capsules
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03855358
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 334
- Registration Number
- NCT03855384
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China